MIR1273C: A Drug Target / Disease Biomarker (G100422821)
MIR1273C: A Drug Target / Disease Biomarker
MIR1273C, also known as interleukin-1273-conjugated, is a protein that is expressed in various tissues throughout the body, including the immune system, skin, and nervous system. It is a member of the interleukin-12 family, which includes several proteins that play important roles in the immune response and inflammation.
One of the unique features of MIR1273C is its ability to interact with the protein PD-L1, which is a negative regulator of immune responses. PD-L1 has been implicated in several diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. MIR1273C has been shown to interact with PD-L1 and can inhibit its effects, which suggests that it may have potential as a drug target or biomarker.
In addition to its potential role in immune regulation, MIR1273C has also been shown to be involved in several other cellular processes that are important for tissue growth and development. For example, it has been shown to play a role in the regulation of cell death, cell proliferation, and cell migration.
MIR1273C has also been shown to be involved in the regulation of pain. Several studies have shown that MIR1273C is involved in the development of pain sensations and that it can be used as a potential therapeutic agent for pain relief.
In conclusion, MIR1273C is a protein that has been shown to interact with PD-L1 and can inhibit its effects. Its potential role in immune regulation, cell death, cell proliferation, and pain regulation makes it an attractive target for further research and potential therapeutic development. Further studies are needed to fully understand the mechanisms of MIR1273C and its potential as a drug or biomarker.
Protein Name: MicroRNA 1273c
The "MIR1273C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR1273C comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR1273H | MIR1275 | MIR1276 | MIR1277 | MIR1278 | MIR1279 | MIR128-1 | MIR128-2 | MIR1280 | MIR1281 | MIR1282 | MIR1283-1 | MIR1283-2 | MIR1284 | MIR1285-1 | MIR1285-2 | MIR1286 | MIR1287 | MIR1288 | MIR1289-1 | MIR1289-2 | MIR129-1 | MIR129-2 | MIR1290 | MIR1291 | MIR1292 | MIR1293 | MIR1294 | MIR1295A | MIR1295B | MIR1296 | MIR1297 | MIR1298 | MIR1299 | MIR1301 | MIR1302-1 | MIR1302-10 | MIR1302-11 | MIR1302-2 | MIR1302-3 | MIR1302-4 | MIR1302-5 | MIR1302-6 | MIR1302-7 | MIR1302-8 | MIR1302-9 | MIR1303 | MIR1304 | MIR1305 | MIR1306 | MIR1307 | MIR130A | MIR130B | MIR132 | MIR1321 | MIR1322 | MIR1323 | MIR1324 | MIR133A1 | MIR133A1HG | MIR133A2 | MIR133B | MIR134 | MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154
